Condition
Nephrotic Syndrome，Idiopathic
Total Trials
5
Recruiting
2
Active
2
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 5 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
40%
2 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
4Total
Not Applicable (1)
P 2 (1)
P 3 (2)
Trial Status
Recruiting2
Not Yet Recruiting1
Unknown1
Completed1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (5)
Showing 5 of 5 trials
NCT07233330Phase 2Not Yet RecruitingPrimary
Obinutuzumab in Adult Rituximab-Dependent Nephrotic Syndrome
NCT06635720Phase 3Recruiting
REduced-dose Steroid PrOtocol for Childhood Nephrotic SyndromE (RESPONSE)
NCT05914155Phase 3Recruiting
Clinical Study of Rituximab for the Treatment for Idiopathic Membranous Nephropathy with Nephrotic Syndrome
NCT02298335Not ApplicableCompletedPrimary
Glucocorticoid in Treatment of Adult Idiopathic Nephrotic Syndrome：a Prospective Observational Study
NCT03786263Unknown
CHILDNEPH The Canadian Childhood Nephrotic Syndrome Study
Showing all 5 trials